Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.53 |
| ▸ | GJB2 | P29033 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | IGF2R | P11717 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301424 | 1.00 | LGALS8 (0.53) | LGALS8LGALS3LGALS4GJB2KDM4E | |
| SCHEMBL2305282 | 0.86 | PYGB (0.47) | GJB2KDM4EPOLBSMN1; SMN2MAPK1 | |
| SCHEMBL3878575 | 0.86 | PYGB (0.47) | GJB2KDM4EPOLBSMN1; SMN2MAPK1 | |
| SCHEMBL21391533 | 0.85 | LGALS3 (0.47) | LGALS8LGALS3LGALS4GJB2KDM4E | |
| SCHEMBL12198733 | 0.85 | PYGB (0.48) | GJB2MAPK1 | |
| SCHEMBL2507136 | 0.85 | PYGB (0.48) | GJB2MAPK1 | |
| SCHEMBL2302510 | 0.85 | PYGB (0.48) | GJB2MAPK1 | |
| SCHEMBL9347500 | 0.85 | GJB2 (0.52) | LGALS8LGALS3LGALS4GJB2KDM4E | |
| SCHEMBL11504400 | 0.85 | GJB2 (0.52) | LGALS8LGALS3LGALS4GJB2KDM4E | |
| SCHEMBL22034095 | 0.85 | GJB2 (0.52) | LGALS8LGALS3LGALS4GJB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569467-B2 | C-glycoside compounds, and method for preparing C-glycoside compounds | ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE RENNES (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20110245490-A1 | C-GLYCOSIDE COMPOUNDS, AND METHOD FOR PREPARING C-GLYCOSIDE COMPOUNDS | ARMOR PROTEINES (FR) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245490-A1 | C-GLYCOSIDE COMPOUNDS, AND METHOD FOR PREPARING C-GLYCOSIDE COMPOUNDS | FUT5, FUT6, CSGALNACT1 | LGALS8 469/4885LGALS3 101/4885LGALS4 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.